Sign in to view content

Subgroup Analyses From the Phase 3 PULSAR Trial of Aflibercept 8 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration

Keyvan Koushan, MD, FRCSC

Video
Published 2023

Related

Episode 9: Rate of Macular Atrophy in HARBOR Study with Dr. SriniVas Sadda
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
TIE2, VEGF, and Integrin Receptor Interplay and its Role in Retinal Disease
Peter K. Kaiser, MD FASRS
Updates from the Field
2020
High-dose Aflibercept Therapy in nAMD and DME Eyes With Suboptimal Response to Standard Dose of Anti-VEGF Therapy: A Retrospective Analysis
Jared S. Nielsen, MD, MBA
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more